Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.

Huang CC, Shiah IS, Chen HK, Mao WC, Yeh YW.

Clin Neuropharmacol. 2008 Jul-Aug;31(4):245-7. doi: 10.1097/WNF.0b013e318157d998.

PMID:
18670250
3.

Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.

Carlson PJ, Merlock MC, Suppes T.

Bipolar Disord. 2004 Oct;6(5):416-20.

PMID:
15383134
4.

Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2004;4(7):1-98. Epub 2004 Jun 1.

5.

A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder.

Corp SA, Gitlin MJ, Altshuler LL.

J Clin Psychiatry. 2014 Sep;75(9):1010-8. doi: 10.4088/JCP.13r08851. Review.

PMID:
25295426
6.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
7.

Alternative approaches to refractory depression in bipolar illness.

Post RM, Leverich GS, Denicoff KD, Frye MA, Kimbrell TA, Dunn R.

Depress Anxiety. 1997;5(4):175-89. Review.

PMID:
9338110
8.

Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefits.

Parker G, Brotchie H, McClure G, Fletcher K.

J Affect Disord. 2013 Oct;151(1):360-4. doi: 10.1016/j.jad.2013.05.093. Epub 2013 Jun 27.

PMID:
23810360
9.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.

Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Review.

PMID:
18501566
10.

Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Tundo A, de Filippis R, Proietti L.

World J Psychiatry. 2015 Sep 22;5(3):330-41. doi: 10.5498/wjp.v5.i3.330.

11.

[Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].

Buhagiar K, Cassar J.

Turk Psikiyatri Derg. 2007 Summer;18(2):179-83. Review. Turkish.

12.

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.

J Clin Psychopharmacol. 2006 Dec;26(6):653-6.

PMID:
17110825
13.

Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.

Alevizos B, Alevizos E, Leonardou A, Zervas I.

Psychiatriki. 2012 Apr-Jun;23(2):143-8.

PMID:
22796912
14.

Do the old psychostimulant drugs have a role in managing treatment-resistant depression?

Parker G, Brotchie H.

Acta Psychiatr Scand. 2010 Apr;121(4):308-14. doi: 10.1111/j.1600-0447.2009.01434.x. Epub 2009 Jul 9.

PMID:
19594481
15.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
16.

Rational polypharmacy in the bipolar affective disorders.

Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, George MS, Callahan A, Leverich G, Frye M.

Epilepsy Res Suppl. 1996;11:153-80. Review.

PMID:
9294735
17.

An open study of methylphenidate in bipolar depression.

El-Mallakh RS.

Bipolar Disord. 2000 Mar;2(1):56-9.

PMID:
11254021
18.

High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report.

Liebrenz M, Hof D, Buadze A, Stohler R, Eich D.

J Med Case Rep. 2012 May 14;6:125. doi: 10.1186/1752-1947-6-125.

19.

Treatment-resistant bipolar disorder.

Gitlin M.

Mol Psychiatry. 2006 Mar;11(3):227-40. Review.

PMID:
16432528
20.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.

Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, Geddes J, Gilbody S, Palmer S, Woolacott N.

Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206. Review.

Supplemental Content

Support Center